Drug makers accuse V Mohan of possible conflict of interest in getting diabetes drug Pioglitazone banned

In January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolonged use of
In January this year, Mohan had written a letter to the Prime Minister’s Office, detailing the risks of bladder cancer caused by the prolonged use of

MSD Pharma, on its defence, has said that the company follows the highest standards of ethics, compliance and regulations, which take precedence over business without any compromise. “Our support to CCEBDM(Certificate Course in Evidence BasedDiabetes Management) is in line with our philosophy of putting patients above all else. This multi-stakeholder programme is being managed by Public Health Foundation of India (PHFI) in association with Mohan’sDiabetes Education Academy, and is successfully addressing the much required capacity development needs among general physicians in the country for a rapidly growing disease like type 2 diabetes.

MSD strongly denies any allegations regarding this programme which have recently appeared in some sections of the media,” said an MSD spokesperson to an email query to ET.

When asked if he should have disclosed his association with MSD while writing the letter, Mohan said that it was just his view and the letter was to alert the ministry about the side affects. But Amar Jessani, editor, Indian Journal of Medical Ethics, says that least doctors can do in such a situation is disclose their association with pharma companies

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s